Study S002780

A 26-week, Randomized, Open-label, 3-arm Parallel, Treat-to-target Study Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin With or Without One Other Oral Anti-diabetic Drug

ClinicalTrials.gov record

Registration

Registration: NCT05333835
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: UNKNOWN
Enrollment: 455
Start: 2022-07-08
Primary completion: 2024-03-30
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:HR17031 injection; DRUG:INS068 injection; DRUG:SHR20004 injection
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Mean Change From Baseline in HbA1c at Week 26 [at Week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.